Neogenomics, Inc.2024财年第二财季实现净利润-18.64百万美元，同比增加23.39%

自选股智能写手08-03

8月3日，Neogenomics, Inc.（NEO.US）公布财报，公告显示公司2024财年第二财季净利润为-18.64百万美元，同比增加23.39%；其中营业收入为1.65亿美元，同比增加12.24%，每股基本收益为-0.15美元。从资产负债表来看，Neogenomics, Inc.（NEO.US）总负债7.27亿美元，其中短期债务2.04亿美元，资产负债比为2.26，流动比率为2.02。机构...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2456923271?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-03 00:20","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2456923271","market":"us","top_or_hot":-1,"title":"Neogenomics, Inc.2024财年第二财季实现净利润-18.64百万美元，同比增加23.39%","media":"自选股智能写手","content":"<div>\n<p>8月3日，Neogenomics, Inc.（NEO.US）公布财报，公告显示公司2024财年第二财季净利润为-18.64百万美元，同比增加23.39%；其中营业收入为1.65亿美元，同比增加12.24%，每股基本收益为-0.15美元。从资产负债表来看，Neogenomics, Inc.（NEO.US）总负债7.27亿美元，其中短期债务2.04亿美元，资产负债比为2.26，流动比率为2.02。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408030020409f09559c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neogenomics, Inc.2024财年第二财季实现净利润-18.64百万美元，同比增加23.39%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeogenomics, Inc.2024财年第二财季实现净利润-18.64百万美元，同比增加23.39%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-03 00:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408030020409f09559c&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月3日，Neogenomics, Inc.（NEO.US）公布财报，公告显示公司2024财年第二财季净利润为-18.64百万美元，同比增加23.39%；其中营业收入为1.65亿美元，同比增加12.24%，每股基本收益为-0.15美元。从资产负债表来看，Neogenomics, Inc.（NEO.US）总负债7.27亿美元，其中短期债务2.04亿美元，资产负债比为2.26，流动比率为2.02。机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408030020409f09559c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEO","symbol_name":"NeoGenomics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408030020409f09559c&s=b","article_id":"2456923271","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408030020409f09559c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2456923271","pubTimestamp":1722615632,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月3日，Neogenomics, Inc.公布财报，公告显示公司2024财年第二财季净利润为-18.64百万美元，同比增加23.39%；其中营业收入为1.65亿美元，同比增加12.24%，每股基本收益为-0.15美元。从资产负债表来看，Neogenomics, Inc.总负债7.27亿美元，其中短期债务2.04亿美元，资产负债比为2.26，流动比率为2.02。机构评级：截至2024年8月3日，当前有12家机构对Neogenomics, Inc.目标价做出预测，其中目标均价为20.67美元，其中最低目标价为16.00美元，最高目标价为30.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"NEO":"NeoGenomics"},"translate_title":"Neogenomics, Inc. achieved net profit of-US $18.64 million in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 23.39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":1},"content_text":"8月3日，Neogenomics, Inc.（NEO.US）公布财报，公告显示公司2024财年第二财季净利润为-18.64百万美元，同比增加23.39%；其中营业收入为1.65亿美元，同比增加12.24%，每股基本收益为-0.15美元。从资产负债表来看，Neogenomics, Inc.（NEO.US）总负债7.27亿美元，其中短期债务2.04亿美元，资产负债比为2.26，流动比率为2.02。机构评级：截至2024年8月3日，当前有12家机构对Neogenomics, Inc.目标价做出预测，其中目标均价为20.67美元，其中最低目标价为16.00美元，最高目标价为30.00美元。公司简介：NeoGenomics Inc 在美国运营着一个以癌症为重点的基因检测实验室网络，并在瑞士运营着一个实验室。该公司分为两个部门，即临床服务部门和高级诊断部门。它提供各种类型的基因和分子检测服务，即细胞遗传学、荧光原位杂交、流式细胞术、免疫组化、分子检测、病理学咨询。先进诊断部门通过支持各种临床试验和研究来支持制药公司的药物开发计划。对于临床服务，其专业诊断服务是根据在线测试订单或书面测试申请表执行的。该公司的大部分收入来自临床服务。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2456923271"}